SPOTLIGHT -
EP. 1: Rapidly Evolving Paradigms for Treating Advanced RCC
EP. 2: Goals of Therapy for Advanced Kidney Cancer
EP. 3: Choosing Frontline Therapy for Metastatic Kidney Cancer
EP. 4: Defining Progression in Metastatic Kidney Cancer
EP. 5: Choosing Post-Progression Therapy for Metastatic RCC
EP. 6: Metastatic RCC: Decision Trees for Second-Line Therapy
EP. 7: Clinical Trials of Post-Progression Therapy for mRCC
EP. 8: Treatment Beyond Progression for Metastatic RCC
EP. 9: CABOSUN Trial of Upfront Cabozantinib in Metastatic RCC
EP. 10: Upfront Immunotherapy for Metastatic Kidney Cancer
EP. 11: VEGF TKI Therapy in the Adjuvant Setting of RCC
EP. 12: Patient Communication About Adjuvant Therapy for RCC
EP. 13: Thoughts on Metastatic Kidney Cancer
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
